Terns Pharmaceuticals, Inc. (TERN)
After hours:
| Previous close | 4.6400 |
| Open | 4.6800 |
| Bid | 4.9000 x 300 |
| Ask | 4.9600 x 100 |
| Day's range | 4.6200 - 4.9300 |
| 52-week range | 3.2600 - 13.5100 |
| Volume | |
| Avg. volume | 896,139 |
| Market cap | 317.44M |
| Beta (5Y monthly) | -0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2700 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.21 |
Simply Wall St.Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswireTerns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024. “We are excited to welcome Melita to the Terns leadership team at a critical stage of growth at the compa
- GlobeNewswire
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in second half of 2024 Cash, cash equivalents and marketable securities of $263 million, expected to provide runway into 2026 FOSTER CITY, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-st
